The epidemiology of psoriasis

Expert Review of Dermatology

Volumn 1, Issue 1, 2006, Pages 63-75

  Neimann, Andrea L ^a   Porter, Steven B ^a   Gelfand, Joel M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

alcohol; cancer; cardiovascular disease; epidemiology; incidence; obesity; prevalence; psoriasis; psoriatic arthritis; smoking

Indexed keywords

EID: 85015637607     PISSN: 17469872     EISSN: 17469880     Source Type: Journal    
DOI: 10.1586/17469872.1.1.63     Document Type: Article

References (157)

1. Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J. Am. Acad. Dermatol. 41 (3 Pt 1), 401–407 (1999).
2. Javitz HS, Ward MM, Farber E, Nail L, Vallow SG. The direct cost of care for psoriasis and psoriatic arthritis in the United States. J. Am. Acad. Dermatol. 46 (6), 850–860 (2002).
3. Gottlieb SL, Gilleaudeau P, Johnson R et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nature Med. 1 (5), 442–447 (1995).
4. Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J. Am. Acad. Dermatol. 46 (1), 1–23 (2002).
5. Langley RG, Krueger GG, Griffiths CE. Psoriasis: epidemiology, clinical features, and quality of life. Ann. Rheum. Dis. 64 (Suppl. 2), 18–23 (2005).
6. Christophers E. Psoriasis - epidemiology and clinical spectrum. Clin. Exp. Dermatol. 26 (4), 314–320 (2001).
7. Naldi L. Epidemiology of psoriasis. Curr. Drug Targets Inflamm. Allergy 3 (2), 121–128 (2004).
8. Naldi L. Inflammatory skin diseases IV: psoriasis. In: The Challenge of Dermato-epidemiology. Williams HC, Strachan DP (Eds). CRC Press LLC, FL, USA, 175–190 (1997).
9. MacMahon B, Pugh TF. Epidemiology: Principles and Methods. Little, Brown and company, Boston, USA (1970).
10. Hennekens CH, Buring JE. Epidemiology in Medicine. Lippincott Williams & Wilkins PA, USA (1987).
11. Bell LM, Sedlack R, Beard CM et al. Incidence of psoriasis in Rochester, Minn, 1980–1983. Arch. Dermatol. 127 (8), 1184–1187 (1991).
12. Gelfand JM, Weinstein R, Porter SB et al. Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. Arch. Dermatol. 141 (12), 1537–1541 (2005).
13. Yip SY. The prevalence of psoriasis in the Mongoloid race. J. Am. Acad. Dermatol. 10 (6), 965–968 (1984).
14. Lindegard B. Diseases associated with psoriasis in a general population of 159,200 middle-aged, urban, native Swedes. Dermatologica 172 (6), 298–304 (1986).
15. Koo J. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol. Clin. 14 (3), 485–496 (1996).
16. Hellgren L. Psoriasis. A statistical, clinical and laboratory investigation of 255 psoriatics and matched healthy controls. Acta Derm. Venereol. 44 (3), 191–207 (1964).
17. Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J. Investig. Dermatol. Symp. Proc. 9 (2), 136–139 (2004).
18. Johnson MT, Roberts J. Skin conditions and related need for medical care among persons 1–74 years. United States, 1971–1974. Vital Health Stat. 11 (212), 1–72 (1978).
19. Kavli G, Forde OH, Arnesen E, Stenvold SE. Psoriasis: familial predisposition and environmental factors. Br. Med. J. 291 (6501), 999–1000 (1985).
20. Ferrandiz C, Bordas X, Garcia-Patos V et al. Prevalence of psoriasis in Spain (Epiderma Project: Phase I). J. Eur. Acad. Dermatol. Venereol. 15 (1), 20–23 (2001).
21. Lomholt G. Psoriasis: prevalence, spontaneous course and genetics. A census study on the prevalence of skin diseases in the Faroe Islands. Dan. Med. Bull. 11, 1–7 (1964).
22. Braathen LR, Botten G, Bjerkedal T. Psoriatics in Norway. A questionnaire study on health status, contact with paramedical professions, and alcohol and tobacco consumption. Acta Derm. Venereol. Suppl. (Stockh.) 142, 9–12 (1989).
23. Barisic-Drusko V, Paljan D, Kansky A, Vujasinovic S. Prevalence of psoriasis in Croatia. Acta Derm. Venereol. Suppl. (Stockh.) 146, 178–179 (1989).
24. Nevitt GJ, Hutchinson PE. Psoriasis in the community: prevalence, severity and patients’ beliefs and attitudes towards the disease. Br. J. Dermatol. 135 (4), 533–537 (1996).
25. Brandrup F, Green A. The prevalence of psoriasis in Denmark. Acta Derm. Venereol. 61 (4), 344–346 (1981).
26. Naldi L, Colombo P, Placchesi R, Chatenoud L, La Vecchia C. Study design and preliminary results from the pilot phase of the PraKtis study: self-reported diagnosis of selected skin diseases in a representative sample of the Italian population. Dermatology 208 (1), 38–42 (2004).
27. Falk ES, Vandbakk O. Prevalence of psoriasis in a Norwegian Lapp population. Acta Derm. Venereol. Suppl. (Stockh.) 182, 6–9 (1993).
28. Gelfand JM, Stern RS, Nijsten T et al. The prevalence of psoriasis in African Americans: results from a population-based study. J. Am. Acad. Dermatol. 52 (1), 23–26 (2005).
29. Rea JN, Newhouse ML, Halil T. Skin disease in Lambeth. A community study of prevalence and use of medical care. Br. J. Prev. Soc. Med. 30 (2), 107–114 (1976).
30. Kavli G, Stenvold SE, Vandbakk O. Low prevalence of psoriasis in Norwegian lapps. Acta Derm. Venereol. 65 (3), 262–263 (1985).
31. Quirk CJ. Skin disease in the Busselton population survey. Med. J. Aust. 1 (12), 569–570 (1979).
32. Duffy DL, Spelman LS, Martin NG. Psoriasis in Australian twins. J. Am. Acad. Dermatol. 29 (3), 428–434 (1993).
33. Braathen LR, Botten G, Bjerkedal T. Prevalence of psoriasis in Norway. Acta Derm. Venereol. Suppl. 142, 5–8 (1989).
34. Farber EM, Nall L. Epidemiology: natural history and genetics. In: Psoriasis (3rd Edition). Roenigk HH, Maibach HI (Eds). Marcel Dekker, Inc., NY, USA, 107–158 (1998).
35. Naldi L. Inflammatory skin diseases IV: psoriasis. In: The Challenge of Dermato-epidemiology. Strachan DP (Ed.). CRC Press, FL, USA, 175–187 (1997).
36. Burch PR, Rowell NR. Mode of inheritance in psoriasis. Arch. Dermatol. 117 (5), 251–252 (1981).
37. Smith AE, Kassab JY, Rowland Payne CM, Beer WE. Bimodality in age of onset of psoriasis, in both patients and their relatives. Dermatology 186 (3), 181–186 (1993).
38. Ferrandiz C, Pujol RM, Garcia-Patos V, Bordas X, Smandia JA. Psoriasis of early and late onset: a clinical and epidemiologic study from Spain. J. Am. Acad. Dermatol. 46 (6), 867–873 (2002).
39. Henseler T, Christophers E. Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J. Am. Acad. Dermatol. 13 (3), 450–456 (1985).
40. Farber EM. Epidemiology: natural history and genetics. In: Psoriasis (2nd Edition). Roenigk HH, Maibach HI (Eds). Marcel Dekker, Inc., NY, USA, 209–258 (1991).
41. Krueger GG, Eyre RW. Trigger factors in psoriasis. In: Dermatologic Clinics. Weinstein GD, Voorhees JJ (Eds). WB Saunders Co., PA, USA, 373–381 (1984).
42. Krueger GG, Duvic M. Epidemiology of psoriasis: clinical issues. J. Invest. Dermatol. 102 (6), S14 –S18 (1994).
43. Farber EM, Nall ML. The natural history of psoriasis in 5,600 patients. Dermatologica 148 (1), 1–18 (1974).
44. Gelfand JM, Feldman SR, Stern RS et al. Determinants of quality of life in patients with psoriasis: a study from the US population. J. Am. Acad. Dermatol. 51 (5), 704–708 (2004).
45. Spuls PI, Witkamp L, Bossuyt PM, Bos JD. The course of chronic plaque-type psoriasis in placebo groups of randomized controlled studies. Arch. Dermatol. 140 (3), 338–344 (2004).
46. Lomholt G. Environment and genetics in psoriasis. Ann. Clin. Res. 8 (5), 290–297 (1976).
47. Gladman DD, Anhorn KA, Schachter RK, Mervart H. HLA antigens in psoriatic arthritis. J. Rheumatol. 13 (3), 586–592 (1986).
48. Brandrup F, Holm N, Grunnet N, Henningsen K, Hansen HE. Psoriasis in monozygotic twins: variations in expression in individuals with identical genetic constitution. Acta Derm. Venereol. 62 (3), 229–236 (1982).
49. Farber EM, Nall ML, Watson W. Natural history of psoriasis in 61 twin pairs. Arch. Dermatol. 109 (2), 207–211 (1974).
50. Watson W, Cann HM, Farber EM, Nall ML. The genetics of psoriasis. Arch. Dermatol. 105 (2), 197–207 (1972).
51. Capon F, Trembath RC, Barker JN. An update on the genetics of psoriasis. Dermatol. Clin. 22 (4), 339–347 (2004).
52. Trembath RC, Clough RL, Rosbotham JL et al. Identification of a major susceptibility locus on chromosome 6p and evidence for further disease loci revealed by a two stage genome-wide search in psoriasis. Hum. Mol. Genet. 6 (5), 813–820 (1997).
53. Veal CD, Clough RL, Barber RC et al. Identification of a novel psoriasis susceptibility locus at 1p and evidence of epistasis between PSORS1 and candidate loci. J. Med. Genet. 38 (1), 7–13 (2001).
54. Capon F, Novelli G, Semprini S et al. Searching for psoriasis susceptibility genes in Italy: genome scan and evidence for a new locus on chromosome 1. J. Invest. Dermatol. 112 (1), 32–35 (1999).
55. Capon F, Munro M, Barker J, Trembath R. Searching for the major histocompatibility complex psoriasis susceptibility gene. J. Invest. Dermatol. 118 (5), 745–751 (2002).
56. Balendran N, Clough RL, Arguello JR et al. Characterization of the major susceptibility region for psoriasis at chromosome 6p21.3. J. Invest. Dermatol. 113 (3), 322–328 (1999).
57. Nair RP, Stuart P, Henseler T et al. Localization of psoriasis-susceptibility locus PSORS1 to a 60-kb interval telomeric to HLA-C. Am. J. Hum. Genet. 66 (6), 1833–1844 (2000).
58. Oka A, Tamiya G, Tomizawa M et al. Association analysis using refined microsatellite markers localizes a susceptibility locus for psoriasis vulgaris within a 111 kb segment telomeric to the HLA-C gene. Hum. Mol. Genet. 8 (12), 2165–2170 (1999).
59. Tamiya G, Shiina T, Oka A et al. New polymorphic microsatellite markers in the human MHC class I region. Tissue Antigens 54 (3), 221–228 (1999).
60. Mallon E, Newson R, Bunker CB. HLA-Cw6 and the genetic predisposition to psoriasis: a meta-analysis of published serologic studies. J. Invest. Dermatol. 113 (4), 693–695 (1999).
61. Asumalahti K, Ameen M, Suomela S et al. Genetic analysis of PSORS1 distinguishes guttate psoriasis and palmoplantar pustulosis. J. Invest. Dermatol. 120 (4), 627–632 (2003).
62. Enerback C, Martinsson T, Inerot A et al. Significantly earlier age at onset for the HLA-Cw6-positive than for the Cw6-negative psoriatic sibling. J. Invest. Dermatol. 109 (5), 695–696 (1997).
63. Samuelsson L, Enlund F, Torinsson A et al. A genome-wide search for genes predisposing to familial psoriasis by using a stratification approach. Hum. Genet. 105 (6), 523–529 (1999).
64. Tomfohrde J, Silverman A, Barnes R et al. Gene for familial psoriasis susceptibility mapped to the distal end of human chromosome 17q. Science 264 (5162), 1141–1145 (1994).
65. Nair RP, Henseler T, Jenisch S et al. Evidence for two psoriasis susceptibility loci (HLA and 17q) and two novel candidate regions (16q and 20p) by genome-wide scan. Hum. Mol. Genet. 6 (8), 1349–1356 (1997).
66. Zheng J, Jin S, Shi R. Confirmation of PSORS psoriasis susceptibility loci in a Chinese population. Arch. Dermatol. Res. 295 (1), 14–18 (2003).
67. Schon MP, Boehncke WH. Psoriasis. Engl. J. Med. 352 (18), 1899–1912 (2005).
68. Bowcock AM. The genetics of psoriasis and autoimmunity. Ann. Rev. Genomics Hum. Genet. 6, 93–122 (2005).
69. Leung DY, Walsh P, Giorno R, Norris DA. A potential role for superantigens in the pathogenesis of psoriasis. J. Invest. Dermatol. 100 (3), 225–228 (1993).
70. Tagami H. Triggering factors. Clin. Dermatol. 15 (5), 677–685 (1997).
71. Rosenberg EW, Noah PW, Zanolli MD et al. Use of rifampin with penicillin and erythromycin in the treatment of psoriasis. Preliminary report. J. Am. Acad. Dermatol. 14 (5 Pt 1), 761–764 (1986).
72. Whyte HJ, Baughman RD. Acute guttate psoriasis and streptococcal infection. Arch. Dermatol. 89, 350–356 (1964).
73. Naldi L, Peli L, Parazzini F, Carrel CF. Family history of psoriasis, stressful life events, and recent infectious disease are risk factors for a first episode of acute guttate psoriasis: results of a case-control study. J. Am. Acad. Dermatol. 44 (3), 433–438 (2001).
74. Johnson TM, Duvic M, Rapini RP, Rios A. AIDS exacerbates psoriasis. N. Engl. J. Med. 313 (22), 14–15 (1985).
75. Duvic M. Papulosquamous disorders associated with human immunodeficiency virus infection. Dermatol. Clin. 9 (3), 523–530 (1991).
76. Ichihashi N, Seishima M, Takahashi T, Muto Y, Kitajima Y. A case of AIDS manifesting pruritic papular eruptions and psoriasiform lesions: an immunohistochemical study of the lesional dermal infiltrates. J. Dermatol. 22 (6), 428–433 (1995).
77. Laurence J, Hodtsev AS, Posnett DN. Superantigen implicated in dependence of HIV-1 replication in T-cells on TCR Vβ expression. Nature 358 (6383), 255–259 (1992).
78. Coopman SA, Johnson RA, Platt R, Stern RS. Cutaneous disease and drug reactions in HIV infection. N. Engl. J. Med. 328 (23), 1670–1674 (1993).
79. Colebunders R, Blot K, Mertens V, Dockx P. Psoriasis regression in terminal AIDS. Lancet 339 (8801), 1110 (1992).
80. Poikolainen K, Reunala T, Karvonen J, Lauharanta J, Karkkainen P. Alcohol intake: a risk factor for psoriasis in young and middle aged men? Br. Med. J. 300 (6727), 780–783 (1990).
81. Naldi L, Parazzini F, Brevi A et al. Family history, smoking habits, alcohol consumption and risk of psoriasis. Br. J. Dermatol. 127 (3), 212–217 (1992).
82. Mills CM, Srivastava ED, Harvey IM et al. Smoking habits in psoriasis: a case control study. Br. J. Dermatol. 127 (1), 18–21 (1992).
83. Poikolainen K, Reunala T, Karvonen J. Smoking, alcohol and life events related to psoriasis among women. Br. J. Dermatol. 130 (4), 473–477 (1994).
84. Naldi L. Cigarette smoking and psoriasis. Clin. Dermatol. 16 (5), 571–574 (1998).
85. Naldi L, Chatenoud L, Linder D et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J. Invest. Dermatol. 125 (1), 61–67 (2005).
86. O’Doherty CJ, MacIntyre C. Palmoplantar pustulosis and smoking. Br. Med. J. 291 (6499), 861–864 (1985).
87. Naldi L, Peli L, Parazzini F. Association of early-stage psoriasis with smoking and male alcohol consumption: evidence from an Italian case-control study. Arch. Dermatol. 135 (12), 1479–1484 (1999).
88. Huriez C, Desmons F, Benoit M, Martin P. Liver biopsy in eczema and other dermatoses. Br. J. Dermatol. 69 (7–8), 237–244 (1957).
89. Behnam S, Behnam S, Koo Y. Alcohol as a risk factor for plaque-type psoriasis. Cutis 76, 181–185 (2005).
90. Chaput JC, Poynard T, Naveau S et al. Psoriasis, alcohol, and liver disease. Br. Med. J. 291 (6487), 25 (1985).
91. Higgins EM, du Vivier AW. Cutaneous disease and alcohol misuse. Br. Med. Bull. 50 (1), 85–98 (1994).
92. Zhang X, Wang H, Te-Shao H, Yang S, Wang F. Frequent use of tobacco and alcohol in Chinese psoriasis patients. Int J. Dermatol. 41 (10), 659–662 (2002).
93. Poikolainen K, Karvonen J, Pukkala E. Excess mortality related to alcohol and smoking among hospital-treated patients with psoriasis. Arch. Dermatol. 135 (12), 1490–1493 (1999).
94. Gupta MA, Schork NJ, Gupta AK, Ellis CN. Alcohol intake and treatment responsiveness of psoriasis: a prospective study. J. Am. Acad. Dermatol. 28 (5 Pt 1), 730–732 (1993).
95. Abel EA, DiCicco LM, Orenberg EK, Fraki JE, Farber EM. Drugs in exacerbation of psoriasis. J. Am. Acad. Dermatol. 15 (5 Pt 1), 1007–1022 (1986).
96. Cox NH, Gordon PM, Dodd H. Generalized pustular and erythrodermic psoriasis associated with bupropion treatment. Br. J. Dermatol. 146 (6), 1061–1063 (2002).
97. Abel EA. Diagnosis of drug-induced psoriasis. Semin. Dermatol. 11 (4), 269–274 (1992).
98. Gaylor ML, Duvic M. Generalized pustular psoriasis following withdrawal of efalizumab. J. Drugs Dermatol. 3 (1), 77–79 (2004).
99. Cather JC, Cather JC, Menter A. Modulating T-cell responses for the treatment of psoriasis: a focus on efalizumab. Expert Opin. Biol. Ther. 3 (2), 361–370 (2003).
100. Hannuksela-Svahn A, Pukkala E, Laara E, Poikolainen K, Karvonen J. Psoriasis, its treatment, and cancer in a cohort of Finnish patients. J. Invest. Dermatol. 114 (3), 587–590 (2000).
101. Boffetta P, Gridley G, Lindelof B. Cancer risk in a population-based cohort of patients hospitalized for psoriasis in Sweden. J. Invest. Dermatol. 117 (6), 1531–1537 (2001).
102. Frentz G, Olsen JH. Malignant tumours and psoriasis: a follow-up study. Br. J. Dermatol. 140 (2), 237–242 (1999).
103. Margolis D, Bilker W, Hennessy S et al. The risk of malignancy associated with psoriasis. Arch. Dermatol. 137 (6), 778–783 (2001).
104. Gelfand JM, Berlin J, Van Voorhees A, Margolis DJ. Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom. Arch. Dermatol. 139 (11), 1425–1429 (2003).
105. Zhang Y, Holford TR, Leaderer B et al. Prior medical conditions and medication use and risk of non-Hodgkin lymphoma in Connecticut United States women. Cancer Causes Control 15 (4), 419–428 (2004).
106. Bhate SM, Sharpe GR, Marks JM, Shuster S, Ross WM. Prevalence of skin and other cancers in patients with psoriasis. Clin. Exp. Dermatol. 18 (5), 401–404 (1993).
107. Lindelof B, Eklund G, Liden S, Stern RS. The prevalence of malignant tumors in patients with psoriasis. J. Am. Acad. Dermatol. 22 (6 Pt 1), 1056–1060 (1990).
108. Stern RS, Vakeva LH. Noncutaneous malignant tumors in the PUVA follow-up study: 1975–1996. J. Invest. Dermatol. 108 (6), 897–900 (1997).
109. Becker N, Deeg E, Rudiger T, Nieters A. Medical history and risk for lymphoma: results of a population-based case-control study in Germany. Eur. J. Cancer 41 (1), 133–142 (2005).
110. Reed WB, Becker SW, Rohde R, Heiskell CL. Psoriasis and arthritis. Clinicopathologic study. Arch. Dermatol. 83, 541–548 (1961).
111. McDonald CJ, Calabresi P. Thromboembolic disorders associated with psoriasis. Arch. Dermatol. 107 (6), 918 (1973).
112. McDonald CJ, Calabresi P. Complication of psoriasis. JAMA 224 (5), 629 (1973).
113. McDonald CJ, Calabresi P. Occlusive vascular disease in psoriatic patients. N. Engl. J. Med. 288 (17), 912 (1973).
114. McDonald CJ, Calabresi P. Psoriasis and occlusive vascular disease. Br. J. Dermatol. 99 (5), 469–475 (1978).
115. Ena P, Madeddu P, Glorioso N, Cerimele D, Rappelli A. High prevalence of cardiovascular diseases and enhanced activity of the renin–angiotensin system in psoriatic patients. Acta Cardiol. 40 (2), 199–205 (1985).
116. Henseler T, Christophers E. Disease concomitance in psoriasis. J. Am. Acad. Dermatol. 32 (6), 982–986 (1995).
117. Mallbris L, Akre O, Granath F et al. Increased risk for cardiovascular mortality in psoriasis in-patients but not in out-patients. Eur. J. Epidemiol. 19 (3), 225–230 (2004).
118. Stern RS, Lange R. Cardiovascular disease, cancer, and cause of death in patients with psoriasis: 10 years prospective experience in a cohort of 1,380 patients. J. Invest. Dermatol. 91 (3), 197–201 (1988).
119. Naldi L, Parazzini F, Peli L, Chatenoud L, Cainelli T. Dietary factors and the risk of psoriasis. Results of an Italian case-control study. Br. J. Dermatol. 134 (1), 101–106 (1996).
120. Vessey MP, Painter R, Powell J. Skin disorders in relation to oral contraception and other factors, including age, social class, smoking and body mass index. Findings in a large cohort study. Br. J. Dermatol. 143 (4), 815–820 (2000).
121. Zachariae H. Prevalence of joint disease in patients with psoriasis: implications for therapy. Am. J. Clin. Dermatol. 4 (7), 441–447 (2003).
122. Gladman DD. Psoriatic arthritis. Rheum. Dis. Clin. North Am. 24 (4), 829–844, (1998).
123. Shbeeb M, Uramoto KM, Gibson LE, O’Fallon WM, Gabriel SE. The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982–1991. J. Rheumatol. 27 (5), 1247–1250 (2000).
124. Gelfand JM, Gladman DD, Mease PJ et al. Epidemiology of psoriatic arthritis in the population of the United States. J. Am. Acad. Dermatol. 53 (4), 573 (2005).
125. Stern RS. The epidemiology of joint complaints in patients with psoriasis. J. Rheumatol. 12 (2), 315–320 (1985).
126. Gladman DD, Shuckett R, Russell ML, Thorne JC, Schachter RK. Psoriatic arthritis (PSA)-an analysis of 220 patients. Q. J. Med. 62 (238), 127–141 (1987).
127. Cohen MR, Reda DJ, Clegg DO. Baseline relationships between psoriasis and psoriatic arthritis: analysis of 221 patients with active psoriatic arthritis. Department of Veterans Affairs Co-operative Study Group on Seronegative Spondyloarthropathies. J. Rheumatol. 26 (8), 1752–1756 (1999).
128. Wong K, Gladman DD, Husted J, Long JA, Farewell VT. Mortality studies in psoriatic arthritis: results from a single out-patient clinic. I. Causes and risk of death. Arthritis Rheum. 40 (10), 1868–1872 (1997).
129. Gladman DD, Cheung C, Ng CM, Wade JA. HLA-C locus alleles in patients with psoriatic arthritis (PsA). Hum. Immunol. 60 (3), 259–261 (1999).
130. Eastmond CJ. Psoriatic arthritis. Genetics and HLA antigens. Baillieres Clin. Rheumatol. 8 (2), 263–276 (1994).
131. Gupta G, Gelfand JM, Lewis JD. Increased risk for demyelinating diseases in patients with inflammatory bowel disease. Gastroenterology 129 (3), 819–826 (2005).
132. Najarian DJ, Gottlieb AB. Connections between psoriasis and Crohn’s disease. J. Am. Acad. Dermatol. 48 (6), 805–821 (2003).
133. Lee FI, Bellary SV, Francis C. Increased occurrence of psoriasis in patients with Crohn’s disease and their relatives. Am. J. Gastroenterol. 85 (8), 962–963 (1990).
134. Hugot JP, Chamaillard M, Zouali H et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease. Nature 411 (6837), 599–603 (2001).
135. Yang H, Plevy SE, Taylor K et al. Linkage of Crohn’s disease to the major histocompatibility complex region is detected by multiple non-parametric analyses. Gut 44 (4), 519–526 (1999).
136. Hugot JP, Laurent-Puig P, Gower-Rousseau C et al. Mapping of a susceptibility locus for Crohn’s disease on chromosome 16. Nature 379 (6568), 821–823 (1996).
137. Hampe J, Schreiber S, Shaw SH et al. A genomewide analysis provides evidence for novel linkages in inflammatory bowel disease in a large European cohort. Am. J. Hum. Genet. 64 (3), 808–816 (1999).
138. Enlund F, Samuelsson L, Enerback C et al. Psoriasis susceptibility locus in chromosome region 3q21 identified in patients from southwest Sweden. Eur. J. Hum. Genet. 7 (7), 783–790 (1999).
139. Matthews D, Fry L, Powles A et al. Evidence that a locus for familial psoriasis maps to chromosome 4q. Nature Genet. 14 (2), 231–233 (1996).
140. Broadley SA, Deans J, Sawcer SJ, Clayton D, Compston DA. Autoimmune disease in first-degree relatives of patients with multiple sclerosis. A UK survey. Brain 123, 1102–1111 (2000).
141. Alemany-Rodriguez MJ, Aladro Y, Amela-Peris R et al. Autoimmune diseases and multiple sclerosis. Rev. Neurol. 40 (10), 594–597 (2005).
142. Midgard R, Gronning M, Riise T, Kvale G, Nyland H. Multiple sclerosis and chronic inflammatory diseases. A case-control study. Acta Neurol. Scand. 93 (5), 322–328 (1996).
143. Gupta MA, Gupta AK. Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis. Br. J. Dermatol. 139 (5), 846–850 (1998).
144. Gupta MA, Schork NJ, Gupta AK, Kirkby S, Ellis CN. Suicidal ideation in psoriasis. Int. J. Dermatol. 32 (3), 188–190 (1993).
145. Polenghi MM, Molinari E, Gala C et al. Experience with psoriasis in a psychosomatic dermatology clinic. Acta Derm. Venereol. Suppl. 186, 65–66 (1994).
146. Gupta MA, Gupta AK, Haberman HF. Psoriasis and psychiatry: an update. Gen. Hosp. Psychiatry. 9 (3), 157–166 (1987).
147. Rubino IA, Sonnino A, Pezzarossa B, Ciani N, Bassi R. Personality disorders and psychiatric symptoms in psoriasis. Psychol. Rep. 77 (2), 547–553 (1995).
148. Vidoni D, Campiutti E, D’Aronco R, De Vanna M, Aguglia E. Psoriasis and alexithymia. Acta Derm. Venereol. Suppl. 146, 91–92 (1989).
149. Gupta MA, Gupta AK, Watteel GN. Early onset (< 40 years age) psoriasis is comorbid with greater psychopathology than late onset psoriasis: a study of 137 patients. Acta Derm. Venereol. 76 (6), 464–466 (1996).
150. Richards HL, Fortune DG, Weidmann A, Sweeney SK, Griffiths CE. Detection of psychological distress in patients with psoriasis: low consensus between dermatologist and patient. Br. J. Dermatol. 151 (6), 1227–1233 (2004).
151. Ginsburg IH, Link BG. Feelings of stigmatization in patients with psoriasis. J. Am. Acad. Dermatol. 20 (1), 53–63 (1989).
152. Devrimci-Ozguven H, Kundakci TN, Kumbasar H, Boyvat A. The depression, anxiety, life satisfaction and affective expression levels in psoriasis patients. J. Eur. Acad. Dermatol. Venereol. 14 (4), 267–271 (2000).
153. Akay A, Pekcanlar A, Bozdag KE, Altintas L, Karaman A. Assessment of depression in subjects with psoriasis vulgaris and lichen planus. J. Eur. Acad. Dermatol. Venereol. 16 (4), 347–352 (2002).
154. Zachariae R, Zachariae C, Ibsen HH, Mortensen JT, Wulf HC. Psychological symptoms and quality of life of dermatology out-patients and hospitalized dermatology patients. Acta Derm. Venereol. 84 (3), 205–212 (2004).
155. Fortune DG, Richards HL, Kirby B et al. Psychological distress impairs clearance of psoriasis in patients treated with photochemotherapy. Arch. Dermatol. 139 (6), 752–756 (2003).
156. Payne RA, Rowland Payne CM, Marks R. Stress does not worsen psoriasis? – a controlled study of 32 patients. Clin. Exp. Dermatol. 10 (3), 239–245 (1985).
157. Picardi A, Pasquini P, Cattaruzza MS et al. Only limited support for a role of psychosomatic factors in psoriasis. Results from a case-control study. J. Psychosom. Res. 55 (3), 189–196 (2003).